Skip to content
StackItSmart
BHuman cohort / observational

Sermorelin

GHRH 1-29

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active 1-29 fragment of human growth hormone-releasing hormone (GHRH 1-29). It binds pituitary GHRH receptors and stimulates the body's own pulsatile release of growth hormone (GH), which in turn raises IGF-1. It was originally developed and FDA-approved (as Geref) both as a diagnostic agent for pituitary GH reserve and for treating GH deficiency in children; it was withdrawn from the US market in 2008 for commercial (not safety) reasons and is now sold off-label/compounded for adult "anti-aging," body-composition, and wellness use. The robust human evidence is for short-term GH stimulation and childhood growth, not for adult anti-aging, fat loss, or muscle-building claims, where high-quality long-term outcome and safety data are essentially absent. Because it raises GH and IGF-1 (a growth factor), the most important theoretical risks are worsening of glucose tolerance/insulin resistance and stimulation of pre-existing malignancy. Repeated dosing of GHRH peptides can trigger anti-GHRH antibody formation, and injection-site reactions are common. Product from unregulated/compounded sources carries purity, sterility, and dosing hazards. This is not a substitute for medical care; use should be supervised by a physician/endocrinologist with baseline and follow-up bloodwork.

Clinical readoutPeptide · gh-secretagogue
Hepatic strainLow
CardiovascularModerate
HPTA suppressionNone
Half-life
Very short
Route
Subcutaneous injection…
Evidence
B
Active
After a single subcutan…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Very short. Sermorelin is a small peptide rapidly cleared from plasma (elimination half-life on the order of minutes); the clinical use of native GHRH(1-29) is explicitly limited by this short half-life, which is why PEGylated and analog forms were developed for less frequent dosing.
Pharmacology

Mechanism of action

Sermorelin is a GHRH receptor agonist. It binds the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl-cyclase-cAMP pathway to stimulate synthesis and pulsatile secretion of endogenous growth hormone. The released GH acts on the liver and peripheral tissues to increase insulin-like growth factor-1 (IGF-1) and IGFBP-3. Unlike exogenous recombinant GH, sermorelin works upstream and preserves negative feedback (somatostatin tone and IGF-1 feedback), so GH release remains pulsatile and physiologic rather than continuously supraphysiologic. Because it depends on a functioning pituitary, it produces little effect where the somatotroph population is destroyed (e.g., pituitary/structural GH deficiency). It does not act on the hypothalamic-pituitary-gonadal axis.
Kinetics

Pharmacokinetics

Half-life

Very short. Sermorelin is a small peptide rapidly cleared from plasma (elimination half-life on the order of minutes); the clinical use of native GHRH(1-29) is explicitly limited by this short half-life, which is why PEGylated and analog forms were developed for less frequent dosing.

Active duration

After a single subcutaneous nighttime dose, GH is released acutely within ~10 minutes and the GH pulse lasts roughly 2 hours; the peptide itself does not persist. Because the pharmacodynamic (GH-releasing) effect is brief, it is dosed to mimic nocturnal GH pulses. Framing is for washout/monitoring windows only, not for evading anti-doping testing.

Route

Subcutaneous injection is the standard route (also given intravenously historically for diagnostic GH-stimulation testing). An intranasal formulation was trialed in children but was abandoned due to poor/declining absorption, local irritation, and antibody formation.

Metabolism & clearance

As a peptide it is degraded by plasma and tissue peptidases/proteases into inactive fragments and amino acids; clearance does not depend on hepatic CYP metabolism. No specific renal- or hepatic-impairment dosing data from primary human trials were identified.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Acutely stimulates endogenous pulsatile GH secretion within ~10 minutes of subcutaneous dosing (verified in aging adults and in GH-deficient children)
  • Raises circulating IGF-1 and IGFBP-3 within about 2 weeks in aging adults
  • In a 5-month RCT of aging men and women, increased skin thickness in both sexes and increased lean body mass, insulin sensitivity, general well-being, and libido in men only, with no significant change in body weight, blood pressure, or bone mineral density
  • In GH-deficient children, increased linear growth/height velocity, though less effectively than recombinant GH
  • IGF-1 response may attenuate over time in some settings (e.g., a return of IGF-1 toward baseline observed in one pediatric infusion study)
  • Marketed adult 'anti-aging,' fat-loss, sleep, and performance benefits are not established by adequate long-term human trials
Safety

Adverse effects by system

Cardiovascular

No cardiovascular toxicity signal in the human trials reviewed; in a 5-month RCT in aging adults, blood pressure and body weight were unaffected. Long-term cardiovascular outcome data are absent, and chronic elevation of GH/IGF-1 carries theoretical cardiovascular concern by analogy to GH excess.

Hepatic

No hepatotoxicity reported. Sermorelin is a peptide not metabolized by hepatic CYP enzymes; general biochemical/liver analyses were unchanged in pediatric GH-deficiency trials.

Endocrine / HPTA

Primary, intended effect is on the somatotropic (GH/IGF-1) axis. Most relevant endocrine adverse effect is impaired glucose tolerance/reduced insulin sensitivity, observed with repeated GHRH-peptide dosing in the elderly; transient hyperlipidemia was reported in one aging-adult RCT. Anti-GHRH antibodies developed in nearly all children given GHRH(1-29) subcutaneously (they waned by ~9 months after stopping). It does not act on the hypothalamic-pituitary-gonadal (HPTA) axis.

Reproductive

No direct human reproductive toxicity data for sermorelin. It is not recommended in pregnancy/lactation: GHRH and its receptor are expressed in human decidual/endometrial stromal tissue, establishing that this axis is biologically active during pregnancy; a GHRH-receptor antagonist (not an agonist like sermorelin) has been shown to induce apoptosis in these cells in vitro. That finding does not demonstrate harm from GHRH-receptor agonism itself, but no study has characterized the effect of an agonist such as sermorelin on decidual tissue, so effects on pregnancy cannot be excluded and should be treated as unstudied.

Neuropsychiatric

No psychiatric adverse effects reported; in the aging-adult RCT, men reported improved general well-being. No adequate data on neuropsychiatric harm.

Renal

No renal toxicity reported in the primary human literature reviewed; no adequate dedicated renal safety data.

Hematologic

No hematologic toxicity reported; complete blood counts were unchanged in trials that monitored safety labs.

Dermatologic

Injection-site reactions are the most common local effect: mild, transient injection-site irritation/reactions (redness, pain, swelling). Increased skin thickness was noted as a physiologic GH effect. Intranasal use caused mucosal burning and rhinorrhea.

Recovery

HPTA suppression & recovery

Suppression: None established — sermorelin acts on the GH/IGF-1 (somatotropic) axis, not the gonadal axis; no primary human data indicate suppression of testosterone, LH, or FSH.

Because sermorelin does not suppress the hypothalamic-pituitary-gonadal axis, no gonadal 'recovery' protocol is indicated for the peptide itself, and no SERM is needed for it. Any concern about testosterone, LH, FSH, fertility, or the effect of stacking it with androgens should be evaluated with baseline and follow-up bloodwork and managed by a physician or endocrinologist, not self-directed. Do not use dual-SERM protocols.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic IGF-1 (keep within age-appropriate reference range; avoid supraphysiologic levels)Fasting glucose and HbA1c (and fasting insulin where available) to detect worsening glucose toleranceFasting lipid panelThyroid function (TSH, free T4)Comprehensive metabolic panel and CBC as general safety labsClinical evaluation for any signs of acromegaly/GH excess

Cadence: Baseline before starting, then at approximately 8-12 weeks after initiation or dose change, and every 3-6 months during continued use, under physician/endocrinologist supervision.

Warning signs — seek care
  • New or worsening high blood sugar (excessive thirst, urination, fatigue)
  • Persistent injection-site reactions, or signs of allergic reaction (rash, swelling, difficulty breathing)
  • Numbness/tingling, joint pain, swelling of hands/feet, or coarsening facial features (possible GH excess/acromegaly-like effects)
  • Headache, vision changes
  • Any new or rapidly changing lump or known cancer history — stop and seek medical evaluation
Do not use if

Contraindications

  • Known hypersensitivity to sermorelin/GHRH or excipients
  • Active or suspected malignancy (GH/IGF-1 is a growth factor; avoid until cleared by oncology)
  • Pregnancy and breastfeeding (no safety data; GHRH axis is active in decidual/endometrial tissue)
  • Diabetes mellitus or impaired glucose tolerance/insulin resistance without specialist supervision (GH stimulation can worsen glycemic control)
  • Untreated hypothyroidism or adrenal insufficiency (blunt/confound the GH response; should be corrected first)
  • Use in children/adolescents except under specialist endocrine care
  • Product from unverified/compounded sources of unknown purity or sterility
Combinations

Interaction profile

  • MajorWith insulin: Metabolic / glucose
  • ModerateWith another GH secretagogue: Metabolic / glucose
  • ModerateWith growth hormone: Metabolic / glucose
  • ModerateWith IGF-1: Metabolic / glucose
  • ModerateWith a GLP-1 / incretin agonist: Metabolic / glucose
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Do not use for 'anti-aging,' fat loss, or muscle gain expecting proven benefit: the strong human evidence is limited to short-term GH stimulation and childhood growth, and long-term adult safety/benefit data are essentially absent.
  • Use only under physician/endocrinologist supervision with baseline and follow-up bloodwork (IGF-1, fasting glucose/HbA1c, lipids, thyroid).
  • Screen for and avoid use with active or suspected cancer; GH/IGF-1 is a growth factor.
  • Avoid in pregnancy and breastfeeding.
  • Monitor glucose closely, especially if diabetic, prediabetic, or older, since GH stimulation can worsen insulin resistance.
  • Stop and seek medical care for signs of GH excess (joint pain, swelling of hands/feet, tingling/carpal tunnel, coarsening features), allergic reaction, persistent injection-site reactions, or new/worsening high blood sugar.
  • Do not source from unregulated or compounded suppliers of unknown purity/sterility; contamination and inaccurate dosing are real hazards.
  • Keep IGF-1 within age-appropriate range rather than pushing it high; higher is not safer.
  • Sermorelin does not require SERM/HPTA 'recovery'; questions about testosterone or fertility belong to an endocrinologist, and dual-SERM protocols should not be used.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Sermorelin/GHRH(1-29) analog given subcutaneously at night (10 mcg/kg) to aging men and women over 5 months acutely released GH within ~10 min (pulse lasting ~2 h), raised IGF-1 and IGFBP-3, increased skin thickness in both sexes and lean body mass/insulin sensitivity/well-being/libido in men only; blood pressure and body weight unaffected; only adverse effect was transient hyperlipidemia.

    RCTEndocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.PMID 9141536 ↗

  2. 02

    Once-daily subcutaneous GHRH(1-29) 30 mcg/kg increased height velocity in GH-deficient children over 1 year, with no adverse glucose changes, no excessive IGF-1 generation, and good overall tolerability.

    RCTPMID 8772599 ↗

  3. 03

    Twice-daily subcutaneous GHRH(1-29) 15 mcg/kg increased growth velocity in children with radiation-induced GH deficiency over 1 year with no adverse biochemical/hormonal changes or attributable adverse events, but was less effective than recombinant GH.

    CohortPMID 9231053 ↗

  4. 04

    In GH-deficient children, GHRH(1-29) produced GHRH antibodies in nearly all patients (which nearly disappeared ~9 months after stopping) with no GH antibodies; IGF-1 rose then fell toward baseline; only mild injection-site irritation in a few patients and no serious side effects; less effective than GH for promoting growth.

    RCTA comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency.PMID 8329830 ↗

  5. 05

    Clinical use of native GHRH(1-29) is limited by its short half-life; injection-site reactions were more frequent than placebo (mild, transient) and repeated dosing produced some impairment of glucose tolerance in the elderly (PEGylated GHRH developed for less frequent dosing).

    RCTPMID 16061831 ↗

  6. 06

    Intranasal GHRH(1-29) in children showed declining absorption/effectiveness, antibody development, and local reactions (sneezing, rhinorrhea, mucosal burning), and was deemed unsuitable in that formulation.

    CohortIntranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth.PMID 8329828 ↗

  7. 07

    Clinical efficacy data for growth hormone secretagogues including sermorelin in adult/hypogonadal body-composition management are largely lacking, limiting understanding of their therapeutic role.

    ReviewBeyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.PMID 32257855 ↗

  8. 08

    GHRH and its receptor splice variant are expressed in human decidual stromal tissue isolated from early-pregnancy patients; a GHRH-receptor ANTAGONIST (JMR-132, not an agonist like sermorelin) induced apoptosis in these cells in vitro via ERK1/2 and JNK signaling. This establishes that the GHRH axis is biologically active in decidual tissue during pregnancy (supporting caution about unstudied agonist effects) but does not itself demonstrate harm from GHRH-receptor agonism.

    PreclinicalPMID 34792103 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice